Central nervous system metastatic epithelial ovarian cancer. Clinical parameters and prognostic factors: a multicenter study of Anatolian Society of Medical Oncology

Central nervous system (CNS) metastasis is a rare event in the course of late stage epithelial ovarian cancer (EOC); however its incidence is increasing in parallel with prolonged survival of patients. Objective: The authors assessed the clinical parameters and potential prognostic features in patients with CNS metastatic disease. Materials and Methods: Clinical data of the 33 patients from the participating centers were retrospectively collected and analyzed. Median age at the time of CNS metastasis was 57 years. Median time from the diagnosis of primary EOC until CNS metastatic disease was 22 months. Nearly half (45.5%) of the patients had single CNS metastatic lesions and all patients in the study group except two received radiotherapy as palliative treatment. Median overall survival (OS) from the time of CNS metastasis was 15 months (0-66). At univariate analysis only number of brain metastatic lesions (p = 0.001) and presence of extracranial disease (p = 0.004) were strongly associated with OS whereas multimodal treatment, size of metastatic lesions, platinum sensitivity, age, grade, and disease stage at presentation were not. Development of CNS metastasis carries a poor prognosis, however patients with single metastatic lesions and only intracranial metastatic disease can have prolonged survival after appropriate palliative management of their disease.

Central nervous system epithelial ovarian cancer; Metastasis; Palliative management.

[1] Koshiyama M., Matsumura N., Konishi I.: “Recent concepts of ovarian carcinogenesis: type I and type II”. Biomed. Res. Int., 2014, 2014, 934261.

[2] Piura E., Piura B.: “Brain metastases from ovarian carcinoma”. ISRN Oncol., 2011, 2011, 527453.

[3] Pietzner K., Oskay-Oezcelik G., El Khalfaoui K., Boehmer D., Lichtenegger W., Sehouli J.: “Brain metastases from epithelial ovarian cancer: overview and optimal management”. Anticancer Res., 2009, 29, 2793.

[4] Ogawa K., Yoshii Y., Nishimaki T., Tamaki N., Miyaguni T., Tsuchida Y., et al.: “Treatment and prognosis of brain metastases from breast cancer”. J. Neurooncol., 2008, 86, 231.

[5] Tiwari V., Pande S.C., Verma K., Goel S.: “Simultaneous integrated boost with intensity modulated radiation therapy in brain oligometastases: A feasible technique for developing countries”. South Asian J. Cancer, 2015, 4, 11.

[6] Pectasides D., Aravantinos G., Fountzilas G., Kalofonos C., Efstathioum E., Karina M., et al.: “Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature”. Anticancer Res., 2005, 25, 3553.

[7] Bruzzone M., Campora E., Chiara S., Giudici S., Merlini L., Simoni C., et al.: “Cerebral metastases secondary to ovarian cancer: still an unusual event”. Gynecol. Oncol., 1993, 49, 37.

[8] Celejewska A., Tukiendorf A., Miszczyk L., Skladowski K., Wydmanski J., Trela-Janus K.: “Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients”. J. Ovarian Res., 2014, 7, 79.

[9] Kolomainen D.F., Larkin J.M., Badran M., A’Hern R.P., King D.M., Fisher C., et al.: “Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence”. J. Clin. Oncol., 2002, 20, 982.

[10] Sehouli J., Pietzner K., Harter P., Munstedt K., Mahner S., Hasenburg A., et al.: “Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study”. Ann. Oncol., 2010, 21, 2201.

[11] Cohen Z.R., Suki D., Weinberg J.S., Marmor E., Lang F.F., Gershenson D.M., et al.: “Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome”. J. Neurooncol., 2004, 66, 313.

[12] LeRoux P.D., Berger M.S., Elliott J.P., Tamimi H.K.: “Cerebral metastases from ovarian carcinoma”. Cancer, 1991, 67, 2194.

[13] Cormio G., Loizzi V., Falagario M., Lissoni A.A., Resta L., Selvaggi L.E.: “Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994”. Int. J. Gynaecol. Obstet., 2011, 114, 133.

[14] D’Andrea G., Roperto R., Dinia L., Caroli E., Salvati M., Ferrante L.: “Solitary cerebral metastases from ovarian epithelial carcinoma: 11 cases”. Neurosurg. Rev., 2005, 28, 120.

[15] Kaminsky-Forrett M.C., Weber B., Conroy T., Spaeth D.: “Brain metastases from epithelial ovarian carcinoma”. Int. J. Gynecol. Cancer, 2000, 10, 366.

[16] Kim Y.Z., Kwon J.H., Lim S.: “A clinical analysis of brain metastasis in gynecologic cancer: a retrospective multi-institute analysis”. J. Korean Med. Sci., 2015, 30, 66.

[17] Geisler J.P., Geisler H.E.: “Brain metastases in epithelial ovarian carcinoma”. Gynecol. Oncol., 1995, 57, 246.

[18] Anupol N., Ghamande S., Odunsi K., Driscoll D., Lele S.: “Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases”. Gynecol. Oncol., 2002, 85, 487.

[19] Teckie S., Makker V., Tabar V., Alektiar K., Aghajanian C., Hensley M., et al.: “Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival”. Radiat. Oncol., 2013, 8, 36.

[20] Pakneshan S., Safarpour D., Tavassoli F., Jabbari B.: “Brain metastasis from ovarian cancer: a systematic review”. J. Neurooncol., 2014, 119, 1.

[21] Ogino A., Hirai T., Fukushima T., Serizawa T., Watanabe T., Yoshino A., et al.: “Gamma knife surgery for brain metastases from ovarian cancer”. Acta Neurochir. (Wien), 2012, 154, 1669.

[22] Hall W.A., Djalilian H.R., Nussbaum E.S., Cho K.H.: “Long-term survival with metastatic cancer to the brain”. Med. Oncol., 2000, 17, 279.

[23] Pothuri B., Chi D.S., Reid T., Aghajanian C., Venkatraman E., Alektiar K., et al.: “Craniotomy for central nervous system metastases in epithelial ovarian carcinoma”. Gynecol. Oncol., 2002, 87, 133.

[24] Melichar B., Urminska H., Kohlova T., Nova M., Cesak T.: “Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature”. Gynecol. Oncol., 2004, 94, 267.